Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
← catalyst calendarSponsored by Ocugen (industry) · OCGN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
60actual
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-23 | actual | When the study began enrolling |
| Primary completion | 2026-02-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-02-03 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Geographic Atrophy
Intervention
- Genetic: OCU410
Primary outcomes
what the primary-completion date above is the date OFSafety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))
measured 12 months (Screening to 12 months post OCU410 administration)
Change in anatomy of ocular structures using Slit Lamp Biomicroscopy
measured 12 months (Screening to 12 months post OCU410 administration)
Change in anatomy of ocular structures using Indirect ophthalmoscopy
measured 12 months (Screening to 12 months post OCU410 administration)
Change from baseline in BCVA (Best Corrected Visual Acuity)
measured 12 months (Screening to 12 months post OCU410 administration)
Change in Low Luminance Visual Acuity
measured 12 months (Screening to 12 months post OCU410 administration)
Change in the Intraocular Pressure (mmHg)
measured 12 months (Screening to 12 months post OCU410 administration)
Permalink · OCGN's whole pipeline · Catalyst calendar · Every registered study · What changed